Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New clinical study uncovers mechanism by which chromium picolinate may enhance insulin sensitivity

29.08.2003


Effective and safe complementary nutrition therapy



The results of a new double-blind randomized placebo controlled human trial of people with type 2 diabetes revealed a potential mechanism that may explain the ability of chromium picolinate to improve insulin resistance in human skeletal muscle – the primary site for glucose metabolism. These data suggest that when chromium picolinate is added to the diet, insulin sensitivity improves for people with diabetes, a chronic disease that affects 194 million people worldwide. The findings were presented by Dr. William T. Cefalu from the University of Vermont College of Medicine, USA at the 18th International Diabetes Federation Congress.

Research suggests that the potential in vivo mechanism of chromium picolinate on insulin action in human skeletal muscle may occur by increasing the activation of Akt phosphorylation -- an intracellular insulin dependent protein that facilitates the uptake of glucose into cells.


"This study demonstrates that those individuals with type 2 diabetes who supplemented their diet with chromium picolinate had an enhanced activity of the protein compared to those who were on placebo," stated Dr. Cefalu. "As this intracellular pathway is implicated in contributing to insulin resistance, this represents a possible mechanism to explain chromium picolinate’s beneficial effect on insulin sensitivity as observed in several clinical studies."

The clinical trial
The double-blind, placebo controlled trial, included two cohorts of subjects with type 2 diabetes who were treated with either sulfonylureas (a class of diabetic drugs that increase insulin secretion), or a diet program. Both groups were randomized to receive either chromium picolinate (1000 mcg) daily or placebo. The most accurate measure of insulin sensitivity, hyperinsulinemic, euglycemic clamp studies, were used to assess the efficacy of glucose uptake on all subjects prior to randomization and at the end of the study. Of the 16 subjects, those randomized to chromium picolinate had a mean increase in insulin sensitivity of 8.9%, while the placebo group had a mean decrease of 3.6%. In addition, insulin-stimulated Akt activation was significantly increased at the end of the study compared to those subjects on placebo. No adverse events were reported.

A Cost Effective Nutrition Therapy
The World Health Organization (WHO) estimates that four to five percent of health budgets are spent on diabetes-related illnesses and that people with diabetes incur medical costs two to five times higher than people without diabetes.

Chromium is an essential mineral that is a co-factor of insulin. "By applying rigorous science, we hope to show it’s potential to improve the quality of patient care for people with diabetes and reduce cost of therapy," said James Komorowski, MS, Vice President of Technical Services and Scientific Affairs, Nutrition 21, Inc., which supplied Chromax? chromium picolinate for the study. Chromax chromium picolinate is the most clinically tested brand of chromium with proven efficacy for support of glucose metabolism. "This new research further supports the large body of scientific evidence showing chromium picolinate is a safe and effective addition to the diet for people with type 2 diabetes seeking optimal control of their blood sugar levels."


Nutrition 21 provided an unrestricted research grant and Chromax® chromium picolinate for the trial. Nutrition 21 is a leading developer and provider of nutritional products, whose health benefits are substantiated by clinical research. The Company markets Chromax chromium picolinate, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com. More information about Chromax is available at www.chromax.com.

Stacey Antine | EurekAlert!
Further information:
http://www.chromax.com
http://www.nutrition21.com/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>